Get the Stockscreener App
3.89
1.15%
-0.04
Sl Science Holding Ltd stock is traded at $3.89, with a volume of 24,409.
It is down -1.15% in the last 24 hours and up +0.00% over the past month.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
See More
Previous Close:
$3.93
Open:
$3.93
24h Volume:
24,409
Relative Volume:
0.35
Market Cap:
$2.18B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-11.50%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.80
$4.1517
1-Week Range:
$3.80
$4.728
52-Week Range:
$3.23
$6.25
Sl Science Holding Ltd Stock (SLBT) Company Profile
Compare SLBT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLBT
Sl Science Holding Ltd
|
3.89 | 2.20B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
481.71 | 121.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
671.66 | 70.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
870.49 | 52.94B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
181.06 | 38.35B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
276.55 | 36.40B | 4.29B | 577.22M | 641.34M | 4.2086 |
Sl Science Holding Ltd Stock (SLBT) Latest News
Lok Sang Leung Net Worth (2026) - GuruFocus
SL Science presents glioblastoma treatment data at WCP 2026 - Investing.com UK
SL Science presents glioblastoma treatment data at WCP 2026 By Investing.com - Investing.com South Africa
Trevi Therapeutics Shares Surge 13% as Biopharma Investors Cheer Cough Drug Data at London Conference - International Business Times Australia
SL Science Holding Limited Exhibits Breakthrough Gamma Delta T Cell Therapy for Glioblastoma at 2026 World Congress of Basic and Clinical Pharmacology - marketscreener.com
SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology - The Manila Times
SL Science Showcases Preclinical Gamma Delta T Cell Study Demonstrating Glioblastoma Elimination at WCP 2026 - Quiver Quantitative
Preclinical γδ T cells eradicated a brain tumor by day 26 at highest dose - Stock Titan
4DMedical Shares Plunge 15.57% to $3.20 as Volatile ASX Healthcare Stock's Wild Ride Continues This Week - International Business Times Australia
Ericsson, Q32 Bio and other big stocks moving lower in Tuesday’s pre-market session - MSN
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
SL Science seeks US orphan drug designation for γδ T-cell therapy - BioWorld News
Net current asset value per share of SL Science Holding Limited – BOATS:SLBT - TradingView
Number of employees of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Gross margin % of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Price to book ratio of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Net margin % of SL Science Holding Limited – NASDAQ:SLBT - TradingView
SL Science Holding Limited (SLBT-Q) Stock Price and News - The Globe and Mail
Enterprise value to revenue forward of SL Science Holding Limited – BOATS:SLBT - TradingView
Net debt of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Cash flow from investing activities of SL Science Holding Limited – BOATS:SLBT - TradingView
Price to earnings forward of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Enterprise value to EBIT forward of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Enterprise value to EBITDA forward of SL Science Holding Limited – NASDAQ:SLBT - TradingView
EBITDA margin % of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Debt to assets ratio of SL Science Holding Limited – BOATS:SLBT - TradingView
EBITDA per share of SL Science Holding Limited – BOATS:SLBT - TradingView
Debt to equity ratio of SL Science Holding Limited – BOATS:SLBT - TradingView
Enterprise value to EBITDA ratio of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Enterprise value to EBITDA forward of SL Science Holding Limited – BOATS:SLBT - TradingView
EBITDA margin % of SL Science Holding Limited – BOATS:SLBT - TradingView
Enterprise value to EBIT forward of SL Science Holding Limited – BOATS:SLBT - TradingView
Price to earnings forward of SL Science Holding Limited – BOATS:SLBT - TradingView
Price to sales forward of SL Science Holding Limited – BOATS:SLBT - TradingView
Price to book forward of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Enterprise value of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Return on equity % of SL Science Holding Limited – BOATS:SLBT - TradingView
Tangible book value per share of SL Science Holding Limited – BOATS:SLBT - TradingView
EBIT per share of SL Science Holding Limited – NASDAQ:SLBT - TradingView
EBIT per share of SL Science Holding Limited – BOATS:SLBT - TradingView
Cash flow from operating activities of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Cash flow from financing activities of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Asset turnover of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Free cash flow of SL Science Holding Limited – BOATS:SLBT - TradingView
Asset turnover of SL Science Holding Limited – BOATS:SLBT - TradingView
Cash per share of SL Science Holding Limited – BOATS:SLBT - TradingView
Total equity of SL Science Holding Limited – BOATS:SLBT - TradingView
EBITDA of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Total liabilities & shareholders' equities of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Total debt of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Long term debt to total equity ratio of SL Science Holding Limited – BOATS:SLBT - TradingView
Sl Science Holding Ltd Stock (SLBT) Financials Data
There is no financial data for Sl Science Holding Ltd (SLBT). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):